Elif Durak-Ediboğlu

Dr. Elif Durak-Ediboğlu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
UKUmut Klayoncu
Umut Klayoncu
YPYavuz Pehli̇vAn
Yavuz Pehli̇vAn
SAServet Akar
Servet Akar
TKTimuçin Kaşi̇fOğlu
Timuçin Kaşi̇fOğlu
GKGezmiş Kimyon
Gezmiş Kimyon
SKSedat Ki̇rAz
Sedat Ki̇rAz
To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of COVID-19 pandemic. A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated and 1394 (74.5%) responded the survey performed by phone call. Patients? data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired for the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). A total of 1,394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had polymerase chain reaction (PCR) confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p=0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p=0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. Long-term effects of the pandemic should be monitored.

30 September 2024 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
DSDevrim Can Sarac
Devrim Can Sarac
EDElif Durak-Ediboğlu
Elif Durak-Ediboğlu
DKDerya Ozer Kaya
Derya Ozer Kaya
GDGozde Duran
Gozde Duran
EAEmre Alp Akatay
Emre Alp Akatay
DBDeniz Bayraktar
Deniz Bayraktar
Objectives: The aim of this study was to translate the Exercise Benefits/Barriers Scale (EBBS) into Turkish and investigate the perceptions of Turkish-speaking patients with different axial spondyloarthritis (axSpA) subtypes regarding exercise benefits and barriers. Patients and methods: This validation study was conducted between June 2018 and December 2021. Patients with axSpA were consecutively assessed regarding physical (age, sex and body mass index) and disease-related characteristics (disease activity, spinal mobility, functional status, quality of life, health status, emotional status, and kinesiophobia). Eligible participants were asked to complete the EBSS and other outcome measurements during their initial visits. EBBS was readministered 7 to 14 days later. Results: One hundred forty-eight patients (89 males, 59 females; mean age: 44.3±11.8 years; range, 19 to 65 years) were included in the study. Of the patients, 108 had radiographic axSpA, and 40 had nonradiographic axSpA. EBBS-Barriers and EBBS-Benefits subscales demonstrated adequate internal consistency (Cronbach’s alphas of 0.82 and 0.95, respectively) and test-retest reliability (intraclass correlation coefficients of 0.837 and 0.807, respectively). No significant differences were observed between axSpA subtypes regarding EBBS-Barriers (p=0.12) and EBBS-Benefits (p=0.10) subscales. Significant relationships were detected between kinesiophobia and EBBS-Barriers scores (r=–0.424, p

7 March 2024 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
HCHaluk Cinakli
Haluk Cinakli
EDElif Durak-Ediboğlu
Elif Durak-Ediboğlu
DSDilek Solmaz
Dilek Solmaz
SAServet Akar
Servet Akar

31 March 2025 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
SKSedat Kiraz
Sedat Kiraz
SAServet Akar
Servet Akar
IEİhSan Ertenli
İhSan Ertenli
SKSüleyman Serdar KOCA
Süleyman Serdar KOCA
EEEmine Duygu Ersözlü
Emine Duygu Ersözlü
UKUmut Klayoncu
Umut Klayoncu
Objectives: This study aimed to examine the frequency and associated factors of extra-musculoskeletal manifestations (EMMs) and peripheral manifestations in an axial spondyloarthritis (axSpA) cohort and their impact on the choice of first biologic treatment. Patients and methods: A total of 1,687 patients with axSpA (978 males, 709 females; mean age: 38.5±11 years) who started their first biologic disease modifying antirheumatic drug (bDMARD) were included from a national prospective database of TReasure between its inception and 2018-2021. Demographic and clinical characteristics, disease-related features, and treatment patterns were compared between patients with and without EMMs or peripheral involvement. Results: Of the patients, 1,283 had radiographic axSpA (r-axSpA), while 404 had nonradiographic axSpA (nr-axSpA). Acute anterior uveitis (AAU) was the most common (11.4%) EMM, and older age, female sex, human leukocyte antigen B27 (HLA-B27) positivity, and a lower Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score were associated with AAU. Female sex, methotrexate use, dactylitis, and higher Ankylosing Spondylitis Disease Activity Score (ASDAS)-serum C-reactive protein (CRP) scores were related to psoriasis (PsO). Inflammatory bowel disease (IBD) and PsO were negatively associated with HLA-B27 positivity. Enthesitis was the most frequent (28.2%) peripheral manifestations, and peripheral arthritis, dactylitis, and enthesitis were independent predictor of each other. In addition, dactylitis and peripheral arthritis were related to more frequent use of conventional disease modifying antirheumatic drugs. In addition, IBD history was associated with less frequent use of etanercept. Older age, less use of sulfasalazine, the absence of enthesitis, and lower Bath Ankylosing Spondylitis Functional Disease Index (BASFI) scores were associated with secukinumab use. Conclusion: Acute anterior uveitis was associated with HLA-B27 positivity, while PsO or IBD were negatively associated with HLA-B27 in patients with axSpA. Peripheral manifestations appeared to be related to each other. Among EMMs, we found that only IBD had an effect on the bDMARD preference.

19 September 2024 in Musculoskeletal Care
Verified
Journal Article
Closed access
EDElif Durak-Ediboğlu
Elif Durak-Ediboğlu
EEEsra Erpek
Esra Erpek
DBDeniz Bayraktar
Deniz Bayraktar
MÖMustafa Özmen
Mustafa Özmen
DSDilek Solmaz
Dilek Solmaz
SAServet Akar
Servet Akar

6 September 2025 in Joint Bone Spine
Verified
Journal Article
Closed access
EDElif Durak-Ediboğlu
Elif Durak-Ediboğlu
HKHasan Kocaayan
Hasan Kocaayan
ÖGÖnay Gercik
Önay Gercik
ZSZeki Soypaçacı
Zeki Soypaçacı
DSDilek Solmaz
Dilek Solmaz
SAServet Akar
Servet Akar